Literature DB >> 2411841

Impaired measles virus-specific cytotoxic T cell responses in multiple sclerosis.

S Jacobson, M L Flerlage, H F McFarland.   

Abstract

To assess whether an virus-specific immune defect may be associated with multiple sclerosis (MS), we have examined the ability to generate measles virus-and influenza virus-specific cytotoxic T cells (CTL) in patients with MS, normal individuals, and other disease controls (ODC). The mean (+/- SEM) measles virus-specific CTL response for normal individuals and ODC was 26.9 +/- 2.9% (N = 17) and 26.7 +/- 2.8% (N = 13) specific lysis, respectively. In contrast, the capacity of MS patients to generate measles virus-specific CTL was markedly diminished. Peripheral blood lymphocytes from MS patients stimulated with measles virus lysed their measles virus-infected autologous B cell line at a group mean level of 6.0 +/- 1.4% (N = 16) specific lysis. MS patients had significantly lower measles virus-specific CTL responses than normal individuals (p less than 0.00001) or ODC (p less than 0.0001). Importantly, this lowered response did not reflect a generalized depressed cytolytic activity of MS patients, since influenza virus-specific CTL and NK activity from these patients were comparable to normals and ODC. Thus, in MS there is a significant depression of measles virus-specific CTL which suggests that this virus-specific immune dysfunction may play a role in the pathogenesis of this disorder.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2411841      PMCID: PMC2187811          DOI: 10.1084/jem.162.3.839

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  18 in total

1.  Measles antibodies in multiple sclerosis.

Authors:  J M ADAMS; D T IMAGAWA
Journal:  Proc Soc Exp Biol Med       Date:  1962-12

Review 2.  The possible viral etiology of multiple sclerosis.

Authors:  R T Johnson
Journal:  Adv Neurol       Date:  1975

3.  Lymphocyte stimulation with measles antigen in multiple sclerosis.

Authors:  M Knowles; M Saunders
Journal:  Neurology       Date:  1970-07       Impact factor: 9.910

Review 4.  The significance of abnormal immune responses in patients with multiple sclerosis.

Authors:  M V Iivanainen
Journal:  J Neuroimmunol       Date:  1981-06       Impact factor: 3.478

Review 5.  Multiple sclerosis (first of two parts).

Authors:  D E McFarlin; H F McFarland
Journal:  N Engl J Med       Date:  1982-11-04       Impact factor: 91.245

6.  Letter: Cellular immunity in multiple sclerosis.

Authors:  D A Fuccillo; J E Abela; R G Traub; M M Gillespie; E L Beadle; J L Sever
Journal:  Lancet       Date:  1975-04-26       Impact factor: 79.321

7.  Cellular immune response to measles, mumps, and vaccinia viruses in multiple sclerosis.

Authors:  H F McFarland; D E McFarlin
Journal:  Ann Neurol       Date:  1979-08       Impact factor: 10.422

8.  Intra-blood-brain barrier measles virus antibody synthesis in multiple sclerosis patients.

Authors:  P Albrecht; W W Tourtellotte; J T Hicks; H Sato; E J Boone; A R Potvin
Journal:  Neurology       Date:  1983-01       Impact factor: 9.910

9.  Multiple sclerosis: distribution of T cell subsets within active chronic lesions.

Authors:  U Traugott; E L Reinherz; C S Raine
Journal:  Science       Date:  1983-01-21       Impact factor: 47.728

10.  A suppression of cellular immunity in patients with multiple sclerosis.

Authors:  V Utermohlen; J B Zabriskie
Journal:  J Exp Med       Date:  1973-12-01       Impact factor: 14.307

View more
  22 in total

1.  Cytotoxic T cells against herpes simplex virus in Behçet's disease.

Authors:  K Hamzaoui; A Kahan; K Ayed; M Hamza
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

2.  HLA class II-restricted presentation of cytoplasmic measles virus antigens to cytotoxic T cells.

Authors:  S Jacobson; R P Sekaly; C L Jacobson; H F McFarland; E O Long
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

3.  Antigen presentation to HLA class II-restricted measles virus-specific T-cell clones can occur in the absence of the invariant chain.

Authors:  R P Sekaly; S Jacobson; J R Richert; C Tonnelle; H F McFarland; E O Long
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

4.  Clonal analysis and in situ characterization of lymphocytes infiltrating human breast carcinomas.

Authors:  T L Whiteside; S Miescher; J Hurlimann; L Moretta; V von Fliedner
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

5.  Chronic restraint stress during early Theiler's virus infection exacerbates the subsequent demyelinating disease in SJL mice: II. CNS disease severity.

Authors:  Erin E Young; Amy N Sieve; Elisabeth G Vichaya; Luis M Carcoba; Colin R Young; Andrew Ambrus; Ralph Storts; C Jane R Welsh; Mary W Meagher
Journal:  J Neuroimmunol       Date:  2010-02-18       Impact factor: 3.478

6.  Mechanism of neuroinflammation: enhanced cytotoxicity and IL-17 production via CD46 binding.

Authors:  Karen Yao; Jhanelle Graham; Yoshimi Akahata; Unsong Oh; Steven Jacobson
Journal:  J Neuroimmune Pharmacol       Date:  2010-07-27       Impact factor: 4.147

7.  Humoral and cellular immune responses to matrix protein of measles virus in subacute sclerosing panencephalitis.

Authors:  S Dhib-Jalbut; H F McFarland; E S Mingioli; J L Sever; D E McFarlin
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

8.  Measles virus-specific cellular immunity in patients with vaccine failure.

Authors:  V H Wu; H McFarland; K Mayo; L Hanger; D E Griffin; S Dhib-Jalbut
Journal:  J Clin Microbiol       Date:  1993-01       Impact factor: 5.948

9.  HLA-DR specific monoclonal antibodies block lymphoproliferative response to measles vaccine in vitro: a pilot study.

Authors:  David M Phelan; Gregory A Poland
Journal:  Vaccine       Date:  2012-08-31       Impact factor: 3.641

10.  Relative increase of inflammatory CD4+ T cells in the cerebrospinal fluid of multiple sclerosis patients and control individuals.

Authors:  F T Rotteveel; B Kuenen; I Kokkelink; A Meager; C J Lucas
Journal:  Clin Exp Immunol       Date:  1990-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.